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Malignant pericardial effusion is known to be a critical complica-
tion in cancer patients due to decreased ventricular stroke volume
and increased diastolic pressure. Symptoms associated with
malignant involvement of the pericardium include dyspnoea,
orthopnoea, hepatomegaly, neck vein distension and electro-
cardiographic changes. The two cancers most frequently associ-
ated with malignant pericardial effusion are breast and lung
carcinomas, while leukaemia, lymphoma, melanoma and gastroin-
testinal malignancies are less frequently involved (DeLoach and
Haynes, 1953; Skhvatsabaju, 1986). It has been estimated that
35% of patients with lung cancer and 25% of breast cancer patients
will be found to have pericardial involvement at autopsy (Shenkai
et al, 1982; Buck et al, 1987). The ultimate outcome for patients
with malignant pericardial effusion depends on numerous factors,
including the performance status, the presence of metastatic
disease, the availability of systemic chemotherapy and the local
management of pericardial involvement. It is generally accepted
that malignant pericardial effusion should only be treated when
symptoms of cardiac tamponade develop (Hancok, 1979). During
the last two decades several treatment approaches have been
reported in the literature, including external radiation therapy
(Cham et al, 1975), surgery (pericardial-pleural window and peri-
cardiectomy) (Campbell et al, 1992) or intrapericardial instillation
of cytostatic drugs, sclerosing agents or radiocolloids (reviewed
by Smith et al, 1974). Although these substances appeared to be
superior in managing malignant pericardial effusion, they were
still found to be only moderately effective in reducing pericardial
fluid formation (Smith et al, 1974). In 1952, Clarke provided the
first evidence that malignant pericardial effusion may be
controlled by intracavitary application of 198Au-colloid suggesting
that radiocolloids have a significant potential for treatment of peri-
cardial involvement. Recently, two studies using intrapericardial
32P-colloid for treatment of malignant pericardial effusion have
been published (Martini et al, 1977; Firusian, 1980). Both reported
high response rates, whereas no complications amongst 39
patients due to the radiocolloid therapy were seen. The encour-
aging results of these two preliminary studies prompted us to set
up a new study using intrapericardial 32P-colloid instillation to
further evaluate the significance of this strategy for treatment of
malignant pericardial effusion.
PATIENTS AND METHODS
32P-colloid as a chromic suspension was supplied by Mallinckrodt
Nuclear (St Louis, MO, USA). 90% of the particles were in the
range of 0.6–2 mm. The physical properties of this compound are
shown in Table 1.
Between November 1982 and February 1998 a total of 36
patients with malignant pericardial effusion were selected for
intrapericardial  32P-colloid therapy. Informed consent was
obtained from all patients. The study was carried out with ethical
committee approval (Muenster University, Germany). All patients
developed pericardial effusion while receiving chemotherapy. The
patients treated comprised: 23 patients with breast cancer (65%),
eight patients with lung cancer (23%) and five patients with other
cancers, mainly lymphomas and gastrointestinal tumors (12%).
The majority of these patients had received multimodal treatment
including chemotherapy and external radiotherapy. In all cases
histological and cytological examinations were performed.
Median age of the group was 62 years (range 42–86). The
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Summary Malignant pericardial effusion is usually treated only when signs of cardiac tamponade develop. Several methods of treatment
have been reported with an overall response rate of approximately 75%. Since our initial study using intrapericardial 32P-colloid instillation as
a treatment modality for pericardial effusion demonstrated a significant higher response rate, this study was conducted to further evaluate the
efficacy of intrapericardial 32P-colloid in terms of response rates and duration of remissions. Intrapericardial instillation of 185–370 MBq
(5–10 mCi)  32P-colloid in 36 patients with malignant pericardial effusion resulted in a complete remission rate of 94.5% (34 patients) whereas
two patients did not respond to treatment due to a foudroyant formation of pericardial fluid. The median duration time was 8 months. No side-
effects were observed. These results suggest that intrapericardial instillation of 32P-colloid is a simple, reliable and safe treatment strategy for
patients with malignant pericardial effusions. Therefore, since further evidence is provided that 32P-colloid is significantly more effective than
external radiation or non-radioactive sclerosing agents, this treatment modality should be considered for the management of malignant
pericardial effusion.
Keywords: pericardial effusion; 32P-colloid; response rates
1955
British Journal of Cancer (1999) 80(12), 1955–1957
© 1999 Cancer Research Campaign
Article no. bjoc.1999.0625
Received 17 August 1998
Revised 14 December 1998
Accepted 2 April 1999
Correspondence to: W Dempketechnique for intrapericardial instillation of 32P-colloid has already
been described (Firusian, 1980). Briefly, the appropriate puncture
side, angle and depth of insertion was accurately determined by
ultrasonography. In addition, the electrocardiography from the
needle tip was monitored continously. Following pericardiocen-
tesis, the intrapericardial catheter was left in place, taped securely
to the entry side, while radiographic and cytological studies were
performed. Prior to 32P-colloid instillation, care was taken that the
pericardial effusion was removed completely. The application of
32P-colloid was then carried out using the same intrapericardial
catheter. According to our initial study (Firusian, 1980) a single
dose of 185 MBq (5 mCi) was administered to 21 patients. In 14
patients, however, two injections of 185 MBq within 2 weeks were
necessary due to rapid pericardial fluid formation. The catheter
was removed immediately after instillation. The distribution of the
radiochemical administered was monitored by scintigraphic scans
of bremsstrahlung.
In all patients treated, blood samples were analysed for 32P con-
tamination immediately after drug injection and then twice weekly
using a Beckman liquid scintillation counter (Beckman, Munich,
Germany).
RESULTS
Characteristics of patients are listed in Table 2 showing doses
instillated and duration of remission. Amongst 36 patients treated,
34 patients achieved a complete, long-lasting remission by
32P-colloid application (response rate: 94.4%). The median dura-
tion of remission was 8 months (range 3–24 months). Two patients
with lung cancer, however, did not respond to the pericardial
32P-colloid instillation (cases 4 and 28); this was due to a rapid
formation of pericardial fluid. Both patients died shortly after
32P-colloid instillation. All patients with a complete remission
after intrapericardial 32P-colloid instillation died due to massive
cancer progression; however, in all patients no signs of
pericardial effusion were found at time of death as examined by
ultrasonography.
In all treated patients serial scintigraphy of bremsstrahlung was
performed. The scintigraphic scans demonstrated that a homoge-
nous distribution of the radioisotope had occurred after application
(Figure 1). No early complications of intrapericardial radiocolloid
therapy were found. In addition, no symptoms of infection or
myocardial irritability were observed. In only one patient (case 33)
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Table 1 Physical properties of 32P-colloid
Emission beta
Energy (maximal) 1.71 MeV
Energy (mean) 0.695 Mev
Range in tissue (maximal) 7–8 mm
Range in tissue (mean) 1–4 mm
Half-life (physical) 14.3 days
Table 2 Results of intrapericardial 32P-colloid instillation in 36 patients
Number Doses (MBq) Effect Duration (months)
of patients
21 185 CR 8.8 (3–24)
13 2 ´ 185 CR 9.3 (3–19)
22   ´ 185 PD –
CR: complete remission; PD: progressive disease.
AB
Figure 1 Typical bremsstrahlung scan following instillation of 5 mCi 32P-colloid in a patient with breast cancer. (A) scan immediately after 32P-colloid
application; (B) scan after 4 days following treatmenta transient tachycardia occurred immediately after instillation;
however, a cardiac treatment was not necessary. No other side-
effects or toxicities were observed.
In all blood samples tested only traces of P-32 activity were
found (< 0.3 nCi ml–1) indicating that no significant capillary
leakage or tissue diffusion had occurred.
DISCUSSION
Management of malignant pericardial effusion still remains a chal-
lenge for every medical oncologist. In the study presented here we
have demonstrated that intrapericardial instillation of 32P-colloid is
a highly effective treatment modality in the management of malig-
nant pericardial effusion. Amongst 36 patients treated, the rate of
long-lasting complete remissions was 94.5%, confirming the
results of the initial study by Firusian (1980).
Since the optimal therapeutic strategy for management of malig-
nant pericardial effusion is still not yet established, several treat-
ment modalities have been reported in the literature. External
beam radiation therapy was shown to be effective in treating
malignant pericardial effusions in some patients, mainly those
with radiosensitive tumours, such as lymphomas and leukaemias
which generally respond favourably to radiotherapy (Terry and
Klegerman, 1970). However, patients with malignant pericardial
effusion secondary to lung or breast cancer responded less
favourably. In 38 patients treated with radiotherapy, Cham et al
(1975) reported an overall response rate of 61%; the mean duration
of relief, however, was only 4 months.
It is generally accepted that surgical intervention should be
considered in those patients who did not respond to radiotherapy
or intrapericardial therapy. Although the response rates are nearly
100%, a significantly high proportion of patients (13%) developed
local recurrence (Mills et al, 1989; Campbell et al, 1992). The
mean survival time was approximately 7 months.
Instillations of cytostatic drugs (e.g. bleomycin, 5-fluorouracil,
cisplatin) or antibiotics (tetracyclines) have also been described
(reviewed in Harbert, 1997). Of these agents, bleomycin and tetra-
cyclines are probably favoured since for both compounds response
rates of 70–80% have been reported (Shepherd et al, 1985; van der
Gaast et al, 1989). The median duration of remission, however,
was only 4 months.
Most recently, Colleoni et al (1998) reported response rates of
23 patients with pericardial effusions after intracavitary treatment
with 15 mg thiotepa (days 1, 3 and 5). Nineteen patients (83%)
responded to treatment. From this study it was concluded that
intracavitary treatment with thiotepa is highly effective and well
tolerated in the treatment of malignant pericardial effusion.
However, when compared with other treatment strategies in the
management of malignant pericardial effusion, the instillation of
32P-colloid was found to be superior. Nowrousian et al (1988)
treated 16 patients with malignant pericardial effusion by
intrapericardial instillation of 32P-colloid. They found a response
rate of 97%, confirming the results we have reported here. Using
the method detailed by Harbert (1997) the total dose of beta
irradiation following pericardial 32P-colloid instillation can be
estimated. Considering the physical properties of 32P-colloid
(Table 1) and a given distribution volume of the isotope of 1000
ml, a single dose of 5 mCi 32P would result in a total irradiation
dose of more than 100 Gy (Harbert, 1997). Since in standard
external beam treatment protocol for radiotherapy of malignant
pericardial effusions only up to 30 Gy were delivered (Cham et al,
1977), this dose estimation clearly indicates that intrapericardial
32P-colloid instillation is more potent in the treatment of malignant
pericardial effusions than external beam radiotherapy.
In summary, the results of our study suggest that treatment of
malignant pericardial effusion with 32P-colloid instillation appears
to be a simple, highly effective and safe treatment modality. There
is evidence that this treatment strategy may be more effective than
external radiation therapy or non-radioactive sclerosing agents.
Thus, its significant potential should be considered for the
management of malignant pericardial effusion.
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